In NSCLC, tumor‐associated CD8+ TRM cells express JAML, which binds to the cancer‐derived CXADR, activating the TRM cells. Higher numbers of CD8+ TRM cells and JAML expression are positively correlated with better patient prognosis. This evidence concerns the gene CD8A and neoplasm.